MediPines, Yorba Linda, Calif., announces that its AGM100 device has been awarded the prestigious Silver Award for Testing and Diagnostic Products in the 2021 Medical Design Excellence Awards. The Medical Design Excellence Awards are an esteemed award program recognizing cutting-edge achievements in medical product design and celebrating the industry’s foremost manufacturers designing and engineering groundbreaking medical devices that are changing patient care worldwide.

The MediPines AGM100 stood out as the only respiratory medical device recognized in the “testing and diagnostic” product category. MediPines AGM100 is the world’s first non-invasive gas exchange analyzer. This advanced respiratory monitoring system was designed to rapidly detect respiratory impairment caused by conditions such as COVID-19, chronic obstructive pulmonary disease (COPD), pneumonia, ARDS, pulmonary edema, and pulmonary embolism.

The device is FDA-cleared and approved for Health Canada COVID-19 Emergency Use. It provides a comprehensive panel of respiratory measurements including blood oxygen levels, oxygen deficit (A-a gradient), P/F ratio, and alveolar oxygen and carbon dioxide levels.

“MediPines is honored by this distinguished MDEA award,” says Steve Lee, CEO of MediPines. “We are delighted that global industry experts are recognizing the need for this kind of innovation in the respiratory field. The MediPines AGM100’s intuitive and user- friendly design is already having a tremendous impact on patient care, and we are excited that others recognize the excellence that has been achieved.” 

Featured image: MediPines’ AGM100 non-invasive gas exchange analyzer is an advanced respiratory monitoring system designed to rapidly detect respiratory impairment caused by conditions such as COVID-19 and COPD. (Courtesy: Medipines)